Top & Current
Fri, October 4, 2024
[ Fri, Oct 04th 2024
] - WOPRAI
Tue, September 24, 2024
[ Tue, Sep 24th 2024
] - WOPRAI
Wed, September 4, 2024
[ Wed, Sep 04th 2024
] - WOPRAI
Tue, August 6, 2024
[ Tue, Aug 06th 2024
] - WOPRAI
Mon, July 22, 2024
[ Mon, Jul 22nd 2024
] - WOPRAI
Tue, June 18, 2024
[ Tue, Jun 18th 2024
] - WOPRAI
Wed, June 5, 2024
[ Wed, Jun 05th 2024
] - WOPRAI
Tue, April 9, 2024
[ Tue, Apr 09th 2024
] - WOPRAI
Tue, March 26, 2024
[ Tue, Mar 26th 2024
] - WOPRAI
Fri, March 1, 2024
[ Fri, Mar 01st 2024
] - WOPRAI
Wed, February 21, 2024
[ Wed, Feb 21st 2024
] - WOPRAI
Fri, February 16, 2024
[ Fri, Feb 16th 2024
] - WOPRAI
Thu, January 25, 2024
[ Thu, Jan 25th 2024
] - WOPRAI
Leonid Timashev Maintained (AXSM) at Buy with Increased Target to $131 on, Oct 4th, 2024
Leonid Timashev of RBC Capital, Maintained "Axsome Therapeutics, Inc." (AXSM) at Buy with Increased Target from $130 to $131 on, Oct 4th, 2024.
Leonid has made no other calls on AXSM in the last 4 months.
There are 7 other peers that have a rating on AXSM. Out of the 7 peers that are also analyzing AXSM, 0 agree with Leonid's Rating of Hold.
These are the ratings of the 7 analyists that currently disagree with Leonid
- Charles Duncan of "Cantor Fitzgerald" Reiterated at Buy and Held Target at $107 on, Friday, September 20th, 2024
- Ami Fadia of "Needham" Reiterated at Strong Buy and Held Target at $130 on, Thursday, September 5th, 2024
- Raghuram Selvaraju of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $180 on, Thursday, September 5th, 2024
- Cerena Chen of "Wells Fargo" Initiated at Buy and Held Target at $140 on, Tuesday, September 3rd, 2024
- Jason Gerberry of "B of A Securities" Upgraded from Hold to Strong Buy and Increased Target to $106 on, Tuesday, August 6th, 2024
- Ashwani Verma of "UBS" Maintained at Strong Buy with Decreased Target to $105 on, Tuesday, August 6th, 2024
- Graig Suvannavejh of "Mizuho" Reiterated at Strong Buy and Held Target at $106 on, Wednesday, June 12th, 2024